

Appendix Table 10. Effects of Adrenergic Drugs on Self-Reported Urinary Continence in Women: Results from Randomized Controlled Clinical Trials (43)*

Author Year	Active Treatment	Control Treatment	(Events/Active Treatment) [Events/Control Treatment]	Relative Risk (95% CI)	Risk Difference (95%CI)	Quality
Yasuda, 1993(136)	Clenbuterol	Placebo	(8/77) [2/88]	4.57 (1.00; 20.88)	0.08 (0.01; 0.16)	No Intention to treat. Double blind. Allocation concealment adequate. Sample size not justified.
Lose, 1988(175)	Norepinephrine	Placebo	(6/23) [3/21]	1.83 (0.52; 6.39)	0.12 (-0.12; 0.35)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
Hilton, 1990(132)	Phenylpropanolamine	Placebo	(0/9) [2/11]	0.24 (0.01; 4.44)	-0.18 (-0.45; 0.08)	No Intention to treat. Double blind crossover RCT. Allocation concealment adequate. Sample size not justified
Lehtonen, 1986(44)	Phenylpropanolamine	Placebo	(15/21) [8/22]	1.96 (1.06; 3.63)	0.35 (0.07; 0.63)	No Intention to treat. Double blind. Allocation concealment adequate. Sample size not justified.
Yasuda, 1993(136)	Clenbuterol	Placebo	(36/77) [21/88]	1.96 (1.26; 3.05)	0.23 (0.09; 0.37)	No Intention to treat. Double blind. Allocation concealment adequate. Sample size not justified.
Wells, 1991(135)	Phenylpropanolamine	Pelvic floor muscle training	(54/75) [42/82]	1.41 (1.09; 1.81)	0.21 (0.06; 0.36)	No Intention to treat (ITT assuming dropouts are failures) Open label. Allocation concealment unclear. Sample size not justified.
Ishiko, 2000(133)	Clenbuterol	Pelvic floor muscle	(10/15) [10/19]	1.27 (0.73; 2.21)	0.14 (-0.19; 0.47)	No Intention to treat (ITT assuming dropouts are

		training Clenbuterol Pelvic floor muscle training	(10/15) [17/22]	0.86 (0.56; 1.32)	-0.11 (-0.40; 0.19)	failures) Allocation concealment not adequate. Sample size not justified.
Wells, 1991(135)	Phenylpropanolamine	<u>Pelvic floor muscle training</u>	(2/52) [9/34] (22/52) [16/34]	0.15 (0.03; 0.63)	-0.23 (-0.38; -0.07)	No Intention to treat (ITT assuming dropouts are failures) Open label. Allocation concealment unclear. Sample size not justified.
Walter, 1990(134)	Phenylpropanolamine + estrogen	Estrogen	(2/15) [2/14]	0.93 (0.15; 5.76)	-0.01 (-0.26; 0.24)	No Intention to treat Double blind. Allocation concealment adequate. Sample size not justified
Hilton, 1990(132)	Phenylpropanolamine + estrogen	Estrogen	(13/29) [3/19]	2.84 (0.93; 8.65)	0.29 (0.05; 0.53)	No Intention to treat. Double blind crossover RCT. Allocation concealment adequate. Sample size not justified
Walter, 1990(134)	Phenylpropanolamine + estrogen	Estrogen	(4/15) [6/14]	0.62 (0.22; 1.75)	-0.16 (-0.50; 0.18)	No Intention to treat Double blind. Allocation concealment adequate. Sample size not justified
Hilton, 1990(132)	Phenylpropanolamine + estrogen	Placebo	(13/29) [2/11] (12/20) [2/11]	2.47 (0.66; 9.20) 3.30 (0.90; 12.15)	0.27 (-0.02; 0.56) 0.42 (0.11; 0.73)	No Intention to treat. Double blind crossover RCT. Allocation concealment adequate. Sample size not justified
	Phenylpropanolamine	Estrogen	(12/20) [0/9]	11.90 (0.78; 181.54)	0.60 (0.35; 0.85)	

*Bold - significant relative risk at 95% confidence level. ITT = intention to treat; PFMT = pelvic floor muscle training; RCT = randomized, controlled trial.